In this scenario, the mechanism of action of monalizumab likely consisted in the improvement of NK cell functions via antibody-dependent-cellular-cytotoxicity (ADCC) by the tumor targeting antibody cetuximab, and not by NKG2A-expressing CD8+ T cells. Here, CD8A is linked to neoplasm.